Taurolidine

牛磺罗定

Report date: 2022/01/14 13:23:58
NME

Base Information

Drug NameTaurolidine
Drug Alias Nametaurolidina牛磺利定taurolidine都洛宁滔罗定 +[10] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionLipopolysaccharide (LPS) inhibitors
TargetsLipopolysaccharide (LPS)
Therapy Area/IndicationsCNS Embryonal TumorPeriodontitisFallopian Tube Neoplasms +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumUnited StatesNetherlands
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesN/A
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesRadboud University Medical CenterUniversitair Ziekenhuis BrusselGeistlich Pharma AG +[4] 
Active IndicationsBacterial Infections
Inactive IndicationsCNS Embryonal TumorPeriodontitisFallopian Tube Neoplasms +[6] 

Other Information

ATC CodeB05CA05
Related LinksWikipediaKEGG